LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.18 3.51

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.1400000000000001

Max

1.23

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.5M -20M
EPS	-0.32
Angestellte	49
EBITDA	6.6M -22M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+132.17% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-6.8M 74M
Vorheriger Eröffnungskurs	-2.33
Vorheriger Schlusskurs	1.18

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Mai 2026, 23:10 UTC

Heiße Aktien

Stocks to Watch: Agilysys, XP

18. Mai 2026, 18:44 UTC

Wichtige Markttreiber

Claritev Shares Recover After Comments About DOJ

18. Mai 2026, 23:55 UTC

Ergebnisse

Review & Preview: Earnings' Last Gasp -- Barrons.com

18. Mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18. Mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18. Mai 2026, 22:25 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18. Mai 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Mai 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

18. Mai 2026, 20:25 UTC

Ergebnisse

Correct: XP 1Q Total Client Assets BRL1.53T

18. Mai 2026, 20:23 UTC

Ergebnisse

XP 1Q Total Client Assets BRL1.53B

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Adj EPS BRL2.49 >XP

18. Mai 2026, 20:19 UTC

Ergebnisse

XP 1Q Rev BRL4.73B >XP

18. Mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18. Mai 2026, 19:00 UTC

Ergebnisse

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18. Mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18. Mai 2026, 18:17 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18. Mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18. Mai 2026, 16:57 UTC

Akquisitionen, Fusionen, Übernahmen

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18. Mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18. Mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18. Mai 2026, 16:54 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Doesn't Set Out Financial Details of Deal

18. Mai 2026, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18. Mai 2026, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18. Mai 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Vinci Buys Canada's Modern Group of Companies

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

132.17% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 132.17%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.